HCPLive Network

Effect of Tolvaptan Management on Outcomes in Patients with Decompensated Heart Failure and Hyponatremia

 
To examine outcomes in patients with decompensated heart failure, volume overload, and hyponatremia who received standard in-hospital management vs. treatment with a vasopressin receptor antagonist, the authors of “Clinical Course of Patients with Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism with Tolvaptan,” published in the Journal of Cardiac Failure, evaluated medical records from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database.
 
To assess “the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes,” researchers examined the records of 232 patients with hyponatremia (defined for this study as serum sodium <135 mEq/L) from the trial’s placebo group and 1,785 non-hyponatremic patients (also from the placebo group). They found that the hyponatremic patients “had less relief of dyspnea despite receiving higher doses of diuretics (59.2% vs 69.2% improved; P < .01) and worse long-term outcomes.”
 
When the researchers looked at the records of 475 hyponatremic patients (including those from the placebo group and those who received treatment with the vasopressin receptor antagonist tolvaptan), they found that treatment with tolvaptan “was associated with greater likelihood of normalization of serum sodium than placebo (58% vs 20% and 64% vs 29% for day 1 and discharge, respectively; P < .001 for both comparisons), greater weight reduction at day 1 and discharge (0.7 kg and 0.8 kg differences, respectively; P < .001 and P = .008), and greater relief of dyspnea (P = .03).”
 
They reported that treatment with tolvaptan had no effect on long-term outcomes compared with placebo. Patients with severe hyponatremia (defined as serum sodium <130 mEq/L) who were treated with tolvaptan experienced reduced cardiovascular morbidity and mortality after discharge.
 
Based on these results, the authors concluded, “In patients with decompensated heart failure and hyponatremia, standard therapy is associated with less weight loss and dyspnea relief, and unfavorable longer-term outcomes compared to those with normonatremia. Tolvaptan is associated with more favorable in-hospital effects and, possibly, long-term outcomes in patients with severe hyponatremia.”
 
 

Further Reading
New research suggests that oral immunotherapy may trigger anaphylaxis in an unusually high percentage of asthmatic teenagers with high-risk food allergies who failed to adhere to their management plan.
Nine percent of top-selling packaged food products in the United States contain partially hydrogenated oils, with most of these products reporting 0 grams of trans fat per serving, according to a study published Aug. 28 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.
A 3-year study of a product meant to help patients dealing with a wide range of conditions including diabetes, hypertension, and weight loss showed positive results according to manufacturer EnteroMedics, Inc.
As national and international health agencies and other groups shift their focus during the current outbreak of the Ebola virus from treatment of those patients with the virus to preventing further large scale events, a team of researchers has reported some success in looking at how Ebola compromises an infected person’s immune system.
Asymptomatic individuals with endomysial antibodies benefit from a gluten-free diet, according to a study published in the September issue of Gastroenterology.
For many patients with chronic conditions such as rheumatoid arthritis, medication adherence is often one of the most challenging aspects of the treatment process, especially when the medications prescribed by their health care professional are prohibitively expensive. A study from Manchester University recently showed that many patients with rheumatoid arthritis are not taking some of their most critical medicines due to rising drug costs.
The leading cause of cancer related deaths in both men and women is lung cancer. The 5-year survival rate of lung cancer is only 16%, as 75% of patients with lung cancer are presented with symptoms of advanced disease.
More Reading